Skip to Main Content

Paper Details

Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
Circ Cardiovasc Qual Outcomes
11
2021
PCSK9, PCSK9i, Proprotein Convertase Subtilisin/Kexin Type 9, cholesterol, low-density lipoprotein cholesterol, patients, physicians, primary care physicians, proprotein convertase subtilisin/kexin
Author NameAffiliation
Kosuke InoueDepartment of Epidemiology (K.I.) university of california los angeles Fielding School of Public Health.
Kosuke InoueGraduate School of Medicine, Kyoto University
Kosuke InoueDepartment of Epidemiology (K.I.) university of california los angeles Fielding School of Public Health.
Kosuke InoueGraduate School of Medicine, Kyoto University
Jose F FigueroaE.J.O.) Harvard T.H. Chan School of Public Health
Jose F FigueroaBrigham and Women's Hospital
Endel J OravE.J.O.) Harvard T.H. Chan School of Public Health
Endel J OravHarvard T.H. Chan School of Public Health
Changyu ShenRichard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center
Changyu ShenHarvard Medical School
Changyu ShenRichard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center
Changyu ShenHarvard Medical School
  • 1 - 12

Datasets

Release 1.2